[Homozygous and compound heterozygous RYR1 mutations. New findings on prevalence and penetrance of malignant hyperthermia]. / Homozygote und "compound"-heterozygote RYR1-Mutationen. Neue Erkenntnisse zu Prävalenz und Penetranz der malignen Hyperthermie.

BACKGROUND: Malignant hyperthermia (MH) is a life-threatening, acute pharmacogenetic disorder mostly due to heterozygous mutations in the ryanodin receptor 1 (RYR1) gene. Diagnosis is generally confirmed by the in vitro contracture test (IVCT). In this study the genotype-phenotype correlation was analyzed and the presumed prevalence of MH is discussed. PATIENTS AND METHODS: After the diagnosis of MH susceptibility by the IVCT DNA samples of 44 patients were analyzed for mutations in the RYR1 gene using the polymerase chain reaction and sequencing. For genotype-phenotype correlation, the mutation analysis data were compared with the IVCT data. RESULTS: Out of the 44 patients tested 13 were identified with a heterozygous mutation, 1 patient with a homozygous mutation (c.1840C>T) and 1 patient with compound heterozygous mutations (c.1840C>T and c.6487C>T). The two patients with two mutated alleles showed a stronger response in the IVCT compared to those with only one mutated allele. Patients with one RYR1 mutation displayed significantly higher contractures in the IVCT than patients without RYR1 mutations. CONCLUSION: In the two patients described the presence of two mutated RYR1 alleles seemed to have an additive effect on the functional restriction of the (RYR1 receptor and to lead to a stronger response both in the IVCT and with regard to clinical signs. The patients with no detected RYR1 mutations possibly have a RYR1 mutation with smaller effects outside the hot spot regions tested and/or false positive IVCT results. The data from a small patient group indicate a substantially higher prevalence of MH with a correspondingly lower penetrance in the German population than previously assumed.

Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.

BACKGROUND AND OBJECTIVE: The in vitro contracture test with halothane and caffeine is the gold standard for the diagnosis of susceptibility to malignant hyperthermia (MH). However, the sensitivity of the in vitro contracture test is between 97 and 99% and its specificity is 78-94% with the consequence that false-negative as well as false-positive test results are possible. 4-Chloro-m-cresol is potentially a more specific test drug for the in vitro contracture test than halothane or caffeine. This multicentre study was designed to investigate whether an in vitro contracture test with bolus administration of 4-chloro-m-cresol can improve the accuracy of the diagnosis of susceptibility to MH. METHODS: Three hundred and fifty-two patients from 11 European MH laboratories participated in the study. The patients were first classified as MH susceptible, MH normal or MH equivocal by the in vitro contracture test according to the European MH protocol. Muscle specimens surplus to diagnostic requirements were used in this study (MH susceptible = 103 viable samples; MH equivocal = 51; MH normal = 204). 4-Chloro-m-cresol was added to achieve a concentration of 75 micromol L(-1) in the tissue bath. The in vitro effects on contracture development and muscle twitch were observed for 60 min. RESULTS: After bolus administration of 4-chloro-m-cresol, 75 micromol L(-1), 99 of 103 MH-susceptible specimens developed marked muscle contractures. In contrast, only two of 204 MH-normal specimens showed an insignificant contracture development following 4-chloro-m-cresol. From these results, a sensitivity rate of 96.1% and a specificity rate of 99.0% can be calculated for the in vitro contracture test with bolus administration of 4-chloro-m-cresol 75 micromol L(-1). Forty-three patients were diagnosed as MH equivocal, but only specimens from 16 patients developed contractures in response to 4-chloro-m-cresol, indicating susceptibility to MH. CONCLUSIONS: The in vitro contracture test with halothane and caffeine is well standardized in the European and North American test protocols. However, this conventional test method is associated with the risk of false test results. Therefore, an improvement in the diagnosis of MH is needed. Regarding the results from this multicentre study, the use of 4-chloro-m-cresol could increase the reliability of in vitro contracture testing.

[Regional distribution of predisposition to maligant hyperthermia in Germany: tate in 1997]. / Die regionale Verbreitung der Veranlagung zur Malignen Hyperthermie in Deutschland: Stand 1997.

Malignant hyperthermia (MH) is a rare autosomally dominantly hereditary and potentially life-threatening disease. The prevalence of the genetic MH predisposition is estimated as 1:10,000 to 1:20,000. In Germany no data on the regional distribution are available. Therefore, the purpose of this investigation is to summarise and present the epidemiological data of all German MH laboratories. Nine German hospitals offer the specific in vitro contracture test to diagnose the MH predisposition. All German MH laboratories carry out the examination in accordance with the standardised protocol of the European Malignant Hyperthermia Group. The laboratories were asked to provide the number of all patients investigated, excluding those suffering from other neuromuscular diseases, separated according to diagnostic groups and their places of residence, the number of the identified MH-families as well as the number of the clinically suspected and investigated MH cases with their places of residence. Eight MH laboratories provided the requested data. Until September 1997 a total of 2620 patients were investigated. In 865 patients (34%) MH suspicion was confirmed (diagnosis: MHS). 1494 patients (56%) were released by investigation from MH-suspicion (diagnosis: MHN). In 261 patients (10%) the MH-predisposition remained unsolved (diagnosis: MHE). 580 MH families were identified. Among 2620 patients 757 were clinically suspected MH cases. 35% of these suspected MH cases were classified as MHS, 10% as MHE and 55% as MHN. The documentation of the patients places of residence classified as MHS and MHE into a map of Germany demonstrates an exhaustive distribution with an increased regional prevalence in the areas of the MH laboratories. This concentration in the area of the MH laboratories becomes even more evident, when the places of residence of the MH suspected cases are demonstrated. In conclusion, the distribution of the MH predisposition is uniform and exhaustive in Germany. The presented regional concentration of clinically suspected MH cases among the MH laboratories is mainly interpreted as an expression of effective regional education and information. Considering the overall incidence of the MH predisposition as described above only 15-20% of the MH patients have so far been identified. The MH laboratories have already released about 10,000 patients from the suspicion of MH predisposition. A preliminary prevalence of at least 1:60,000 to 1:80,000 in Germany can be estimated according to the presented data.

Checking the carotid pulse check: diagnostic accuracy of first responders in patients with and without a pulse.

International guidelines for cardiopulmonary resuscitation (CPR) in adults advocate that cardiac arrest be recognized within 5-10 s, by the absence of a pulse in the carotid arteries. However, validation of first responders' assessment of the carotid pulse has begun only recently. We aimed (1) to develop a methodology to study diagnostic accuracy in detecting the presence or absence of the carotid pulse in unresponsive patients, and (2) to evaluate diagnostic accuracy and time required by first responders to assess the carotid pulse. In 16 patients undergoing coronary artery bypass grafting, four groups of first responders (EMT-1: 107 laypersons with basic life support (BLS) training; EMT-2: 16 emergency medical technicians (EMTs) in training; PM-1: 74 paramedics in training; PM-2: 9 certified paramedics) performed, single-blinded and randomly allocated, carotid pulse assessment either during spontaneous circulation, or during non-pulsatile cardiopulmonary bypass. Time to diagnosis of carotid pulse status, concurrent haemodynamics and diagnostic accuracy were recorded. In 10% (6/59), an absent carotid pulse was not recognized as pulselessness. In 45% (66/147), a pulse was not identified despite a carotid pulse with a systolic pressure > or = 80 mmHg. Thus, although sensitivity of all participants for central pulselessness approached 90%, specificity was only 55%. Both sensitivity and, to a lesser degree, specificity improved with increasing training; blood pressure or heart rate had no significant effect. The median diagnostic delay was 24 s (minimum 3 s). When no carotid pulse was found, delays were significantly longer (30 s: minimum 13 s), than when a carotid pulse was identified (15 s; minimum 3 s) (P < 0.0001). Of all participants, only 15% (31/206) produced correct diagnoses within 10 s. Only 1/59 (2%) identified pulselessness correctly within 10 s. Our cardiopulmonary bypass model of carotid pulse assessment proved to be feasible and realistic. We conclude that recognition of pulselessness by rescuers with basic CPR training is time-consuming and inaccurate. Both intensive retraining of professional rescuers and reconsideration of guidelines about carotid pulse assessment are warranted.